Skip to main content
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc · Earnings Calls, Transcripts & Webcasts

Track KNSA — free
$93.90 +0.36 (+0.38%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20 545.23K Avg daily vol (3M) 658.72K

Kiniksa Pharmaceuticals International, plc Webcasts

Earnings calls, investor updates, investor days and conferences for Kiniksa Pharmaceuticals International, plc (KNSA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-16
Kiniksa Pharmaceuticals International, plc (KNSA) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-27
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Confident tone Penetration and market expansion Financial strength and profitability KPL-387 clinical development
Revenue
$285.97M
▲ 58.1% YoY
Diluted EPS
$0.56
▲ 143.5% YoY
Gross margin
90.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-09
Kiniksa Pharmaceuticals International, plc (KNSA) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Kiniksa Pharmaceuticals International, plc (KNSA) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Confident tone KPL-387 Phase 3 advancement ARCALIST commercial momentum ACC clinical guidelines dissemination
Revenue
$243.60M
▲ 55.4% YoY
Diluted EPS
$0.30
▲ 30.4% YoY
Gross margin
90.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) July 28, 2026 Investor Update
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-09
Kiniksa Pharmaceuticals International, plc (KNSA) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Kiniksa Pharmaceuticals International, plc (KNSA) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call
Revenue
$214.27M
▲ 55.5% YoY
Diluted EPS
$0.27
▲ 145.5% YoY
Gross margin
90.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Confident tone ARCALYST commercial growth KPL-1161 early pipeline KPL-387 pipeline development
Revenue
$202.13M*
▲ 65% YoY
Gross margin
89.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Confident tone Patient Adherence and Duration of Therapy ARCALYST Commercial Growth Recurrent Pericarditis Market Penetration
Revenue
$180.85M
▲ 61.2% YoY
Diluted EPS
$0.23
Gross margin
88.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript
Confident tone ARCALYST commercial execution KPL-387 pipeline (recurrent pericarditis) Recurrent pericarditis market leadership
Revenue
$156.80M
▲ 44.3% YoY
Diluted EPS
$0.23
Gross margin
88.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Confident tone ARCALYST commercial performance and guidance raise KPL-387 pipeline development in recurrent pericarditis Medicare Part D / IRA affordability changes
Revenue
$137.78M
▲ 72.5% YoY
Diluted EPS
$0.11
Gross margin
87.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Confident tone KPL-387 program announcement ARCALYST commercial growth Pipeline portfolio prioritization
Revenue
$122.54M*
▲ 46.9% YoY
Gross margin
85.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript
Confident tone ARCALYST commercial execution First recurrence (earlier-line) prescribing Abiprubart pipeline in Sjogren's disease
Revenue
$112.21M
▲ 67.4% YoY
Diluted EPS
$-0.18
Gross margin
82.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Phase 2b Guidance and outlook
Revenue
$108.63M
▲ 52% YoY
Diluted EPS
$-0.06
▼ 128.6% YoY
Gross margin
88.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2024 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Disease RESONANCE Registry and steroid-sparing paradigm
Revenue
$79.86M
▲ 65.2% YoY
Diluted EPS
$-0.25
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2023 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart Phase II clinical data Abiprubart Phase IIb in new indication
Revenue
$83.39M*
▲ 34.8% YoY
Gross margin
88.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2023 Earnings Call Transcript
Revenue
$67.05M
▼ 32.4% YoY
Diluted EPS
$-0.20
▼ 106.3% YoY
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2023 Earnings Call Transcript
Revenue
$71.47M
▲ 165% YoY
Diluted EPS
$0.21
Gross margin
89.2%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2023 Earnings Call Transcript
Revenue
$48.34M
▲ 50.2% YoY
Diluted EPS
$-0.18
Gross margin
85.4%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2022 Earnings Call Transcript
Revenue
$61.88M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2022 Earnings Call Transcript
Revenue
$99.14M
▲ 719.6% YoY
Diluted EPS
$3.18
Gross margin
93.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2022 Earnings Call Transcript
Revenue
$26.97M
▲ 250.1% YoY
Diluted EPS
$-0.29
Gross margin
81.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2022 Earnings Call Transcript
Revenue
$32.19M
Diluted EPS
$-0.36
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2021 Earnings Call Transcript
Net income
−$36.33M*
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2021 Earnings Call Transcript
Revenue
$12.10M
Diluted EPS
$-0.44
Gross margin
77.1%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2021 Earnings Call Transcript
Revenue
$7.70M
Diluted EPS
$-0.61
Gross margin
68.0%
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2019 Earnings Call
Net income
−$31.80M*
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 webcasts
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 280 filings 272 filers Visit website Investor relations